Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stereotaxis Inc (STXS)

Stereotaxis Inc (STXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 221,180
  • Shares Outstanding, K 93,325
  • Annual Sales, $ 26,920 K
  • Annual Income, $ -24,050 K
  • EBIT $ -24 M
  • EBITDA $ -23 M
  • 60-Month Beta 1.47
  • Price/Sales 8.25
  • Price/Cash Flow N/A
  • Price/Book 34.59

Options Overview Details

View History
  • Implied Volatility 195.15% (+51.42%)
  • Historical Volatility 70.76%
  • IV Percentile 94%
  • IV Rank 38.83%
  • IV High 426.53% on 03/14/25
  • IV Low 48.26% on 08/11/25
  • Expected Move (DTE 8) 0.26 (10.54%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 236
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 9,450
  • Open Int (30-Day) 9,839
  • Expected Range 2.17 to 2.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.07
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.09 +15.79%
on 11/18/25
2.56 -5.47%
on 11/12/25
-0.43 (-15.09%)
since 11/11/25
3-Month
2.09 +15.79%
on 11/18/25
3.59 -32.59%
on 10/09/25
-0.46 (-15.97%)
since 09/11/25
52-Week
1.54 +57.14%
on 04/07/25
3.59 -32.59%
on 10/09/25
+0.18 (+8.04%)
since 12/11/24

Most Recent Stories

More News
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company...

STXS : 2.42 (+2.11%)
Stereotaxis Reports 2025 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results...

STXS : 2.42 (+2.11%)
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received...

STXS : 2.42 (+2.11%)
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 2.42 (+2.11%)
Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE...

STXS : 2.42 (+2.11%)
Lake Street Reaffirms Their Buy Rating on Stereotaxis (STXS)

Lake Street analyst Frank Takkinen reiterated a Buy rating on Stereotaxis today and set a price target of $4.00. The company’s shares closed last Friday at $3.07.Elevate Your Investing Strategy: Take...

STXS : 2.42 (+2.11%)
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias

ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus,...

STXS : 2.42 (+2.11%)
Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first...

STXS : 2.42 (+2.11%)
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful...

STXS : 2.42 (+2.11%)
Stereotaxis to Present at Upcoming Investor Conferences

ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David...

STXS : 2.42 (+2.11%)

Business Summary

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires...

See More

Key Turning Points

3rd Resistance Point 2.54
2nd Resistance Point 2.49
1st Resistance Point 2.45
Last Price 2.42
1st Support Level 2.36
2nd Support Level 2.31
3rd Support Level 2.27

See More

52-Week High 3.59
Fibonacci 61.8% 2.81
Fibonacci 50% 2.57
Last Price 2.42
Fibonacci 38.2% 2.32
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar